Exchange: NASDAQ·Updated 07:48 PM EDT

NXTS News

News
all
press releases
Nexentis Puts Its Drug-Discovery Engine in the Cloud and the Bigger Story Is What Comes Next
Nexentis Technologies (NASDAQ:NXTS) is giving its MitoCareX Bio subsidiary a more powerful digital backbone as the company pushes deeper into computational drug discovery. MitoCareX deployed its Computational Drug Discovery Infrastructure on Google Cloud Platform (NASDAQ:GOOG), a move designed to expand computing capacity while improving data governance, access controls and operational flexibility. In other words, Nexentis is not merely adding cloud storage; it is building infrastructure intended to support a discovery operation that is becoming increasingly computational.
24-7 Market News
AI, Biotech, And Healthcare Catalysts Drive Momentum
Several emerging public companies are attracting attention as artificial intelligence, healthcare innovation, medical technology, and international commercialization strategies continue converging across the market. From AI-powered drug discovery and regenerative medicine expansion to precision dermatology and medical device innovation, recent developments highlight how smaller companies are positioning themselves around some of the fastest-growing sectors in healthcare and technology. $TGNT, $NXTS, $AZTR, $ADTX, $TNON, $PFE
24-7 Market News
Dow Jumps 200 Points; Outdoor Holding Shares Fall After Q4 Results
US stocks rise, Dow up over 200 points. Financial shares jump 0.9% while communication services stocks fall 2.3%. Nexentis Technologies Inc shares surge 208%.read more...
Benzinga
AI Meets Mitochondrial Drug Discovery
Artificial intelligence continues to reshape pharmaceutical research, and the latest example comes from Nexentis Technologies (NASDAQ:NXTS), whose wholly owned subsidiary, MitoCareX Bio, has launched a new drug discovery initiative aimed at accelerating the identification of novel small-molecule therapies.
24-7 Market News

Advertisement|Remove ads.